Open AccessUse of Curcumin with Tyrosine Kinase Inhibitors in EGFR-mutant Non-Small Cell Lung Cancer. A Phase I prospective Cohort Trial
Author(s) -
Goulnar Kasymjanova
Publication year - 2021
Publication title -
alternative complementary and integrative medicine
Language(s) - English
Resource type - Journals
ISSN - 2470-7562
DOI - 10.24966/acim-7562/100201
Subject(s) - lung cancer , medicine , curcumin , oncology , randomized controlled trial , tyrosine kinase , clinical trial , prospective cohort study , cancer , pharmacology , receptor
Our study is the first prospective clinical study using combination of curcumin and EGFR-TKIs in metastatic lung cancer patients. The future randomized larger-scale clinical trials using this combination is feasible and safe. RCT will seek to assess the potential effects on survival and response to TKIs.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom